A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of the Recombinant human anti-PD-1 Monoclonal Antibody for Subjects with Advanced Solid Tumors
Latest Information Update: 12 Apr 2023
At a glance
- Drugs Zimberelimab (Primary)
- Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gastric cancer; Gastrointestinal cancer; Hodgkin's disease; Liver cancer; Lung cancer; Lymphoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Guangzhou Gloria Biosciences
- 07 Apr 2023 Status changed from active, no longer recruiting to completed.
- 01 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 07 Mar 2021 Results published in the European Journal of Cancer